百济神州(688235) - 2024 Q3 - 季度财报

Revenue and Financial Performance - Revenue for the third quarter reached 7,139,451 thousand RMB, a 26.9% increase year-over-year[2] - Year-to-date revenue totaled 19,135,857 thousand RMB, up 48.6% compared to the same period last year[2] - Total revenue for the first three quarters of 2024 reached 19,135,857 thousand RMB, a significant increase from 12,875,236 thousand RMB in the same period of 2023[19] - Adjusted operating profit for the third quarter was 644 million RMB, compared to an adjusted operating loss of 1.47 billion RMB in the same period last year[11] - Year-to-date adjusted operating profit was 52 million RMB, compared to an adjusted operating loss of 34.89 billion RMB in the same period last year[11] - Operating cash flow from sales of goods and services for the first three quarters of 2024 was 19,425,796 thousand RMB, up from 11,359,135 thousand RMB in the same period of 2023[21] - Operating cash inflow totaled $19,749,714, an increase from$11,932,632 in the previous period[22] - Operating cash outflow was $21,590,850, up from$17,334,221[22] - Net cash flow from operating activities was -$1,841,136, improving from -$5,401,589[22] - Cash received from other operating activities was $200,758, down from$427,518[22] - Cash paid for goods and services was $9,426,577, up from$7,085,090[22] - Cash paid to employees was $7,185,526, up from$6,392,513[22] Net Loss and Earnings - Net loss attributable to shareholders for the third quarter was -809,305 thousand RMB, a 160.4% increase in loss year-over-year[2] - Net loss for the first three quarters of 2024 was 3,686,694 thousand RMB, slightly improved from 3,878,105 thousand RMB in the same period of 2023[19] - Basic and diluted earnings per share for the first three quarters of 2024 were both -2.71 RMB, compared to -2.85 RMB in the same period of 2023[20] R&D Investment - R&D investment for the third quarter was 3,537,939 thousand RMB, accounting for 49.55% of revenue[3] - Year-to-date R&D investment reached 10,165,926 thousand RMB, a 10.8% increase year-over-year[3] - R&D expenses for the first three quarters of 2024 amounted to 10,165,926 thousand RMB, up from 9,177,446 thousand RMB in the same period of 2023[19] Assets and Liabilities - Total assets at the end of the reporting period were 40,855,913 thousand RMB, a slight decrease of 0.6% compared to the end of the previous year[3] - Shareholders' equity at the end of the reporting period was 24,172,410 thousand RMB, a 3.7% decrease compared to the end of the previous year[3] - Total assets as of September 30, 2024, stood at 40,855,913 thousand RMB, compared to 41,121,675 thousand RMB at the end of 2023[17] - Total liabilities as of September 30, 2024, were 16,683,503 thousand RMB, up from 16,018,333 thousand RMB at the end of 2023[17] - Accounts receivable increased to 3,989,938 thousand RMB as of September 30, 2024, from 2,538,268 thousand RMB at the end of 2023[17] Cash and Cash Equivalents - Cash and cash equivalents decreased to 12,244,674 thousand RMB as of September 30, 2024, from 15,124,881 thousand RMB at the end of 2023[17] - Ending cash and cash equivalents balance was $12,179,613, down from$15,037,890 at the beginning of the period[22] - Cash and cash equivalents decreased by $2,858,277, compared to a decrease of$2,283,799 in the prior period[22] Non-Operating Income - Non-operating income for the third quarter included 77,583 thousand RMB from fair value changes and disposal of financial assets and liabilities[4] Shareholding Structure - Total issued shares of the company amount to 1,386,034,320, with 91.70% (1,270,979,060 shares) issued overseas and 8.30% (115,055,260 shares) issued domestically in RMB[12] - Amgen holds 246,269,426 shares, representing 17.77% of the total issued shares[12] - HHLR Fund, L.P. and its affiliates hold 142,888,241 shares, representing 10.31% of the total issued shares[12] - Baker Brothers Life Sciences, L.P. and its affiliates hold 138,757,831 shares, representing 10.01% of the total issued shares[12] - Capital Research and Management Company and its affiliates hold 108,530,277 shares, representing 7.83% of the total issued shares[12] - Hong Kong Securities Clearing Company holds 8,549,742 shares, representing 0.62% of the total issued shares[12] - Central Enterprise Rural Industry Investment Fund Co., Ltd. holds 4,790,454 shares, representing 0.35% of the total issued shares[12] - Guangzhou High-Tech Zone Technology Holding Group Co., Ltd. holds 4,790,454 shares, representing 0.35% of the total issued shares[13] - Bank of Communications Co., Ltd. - Wanjia Industry Preferred Hybrid Securities Investment Fund (LOF) holds 3,000,000 shares, representing 0.22% of the total issued shares[13] - China Construction Bank Co., Ltd. - ICBC Credit Suisse Frontier Medical Equity Securities Investment Fund holds 2,600,122 shares, representing 0.19% of the total issued shares[13] Cash Flow from Investing and Financing Activities - Net cash flow from investing activities was -$2,197,288, compared to$2,823,248 previously[22] - Net cash flow from financing activities was $1,192,649, up from$250,615[22]